Secunderabad Healthcare Ltd.
| BSE: 524540 | Sector: Health care |
| NSE: N.A. | ISIN Code: INE930C01016 |
| BSE 00:00 | 04 Mar | Secunderabad Healthcare Ltd |
| NSE 05:30 | 01 Jan | Secunderabad Healthcare Ltd |
| OPEN | 6.17 |
| PREVIOUS CLOSE | 5.99 |
| VOLUME | 309707 |
| 52-Week high | 6.17 |
| 52-Week low | 0.00 |
| P/E | |
| Mkt Cap.(Rs cr) | 50 |
| Buy Price | 5.77 |
| Buy Qty | 25.00 |
| Sell Price | 6.10 |
| Sell Qty | 492.00 |
Secunderabad Healthcare Ltd. (SECUNDHEALTH) - Net Profit
Net Profit
| COMPANY | LATEST(Rs) | CHG | CHG(%) | Net Profit (Rs crore) |
| Aurobindo Pharma | 549.90 | -12.25 | -2.18 | 3112.91 |
| Cipla | 935.00 | 2.15 | 0.23 | 2468.28 |
| Dr Reddy's Labs | 3878.45 | -45.05 | -1.15 | 2186.40 |
| Sun Pharma.Inds. | 885.50 | 3.40 | 0.39 | 2139.70 |
| Divi's Lab. | 4236.70 | -47.05 | -1.10 | 1954.72 |
| Alkem Lab | 2923.70 | 20.70 | 0.71 | 1685.08 |
| Glenmark Pharma. | 391.45 | -2.60 | -0.66 | 1649.45 |
| Zydus Lifesci. | 344.90 | 4.20 | 1.23 | 1476.20 |
| Lupin | 682.95 | -13.35 | -1.92 | 1258.62 |
| Alembic Pharma | 741.20 | -0.25 | -0.03 | 1175.39 |
| Ipca Labs. | 985.40 | 10.45 | 1.07 | 1140.77 |
| Torrent Pharma. | 2591.90 | 10.55 | 0.41 | 1137.85 |
| Gland Pharma | 3095.95 | 100.55 | 3.36 | 997.01 |
| Laurus Labs | 537.85 | -0.60 | -0.11 | 956.11 |
| Sanofi India | 6629.65 | -118.85 | -1.76 | 944.40 |
| Abbott India | 16459.85 | -82.55 | -0.50 | 690.69 |
| Ajanta Pharma | 1666.10 | -44.95 | -2.63 | 675.64 |
| Wockhardt | 235.65 | 1.15 | 0.49 | 593.29 |
| Granules India | 240.95 | 1.70 | 0.71 | 552.78 |
| Pfizer | 4217.50 | -35.20 | -0.83 | 497.61 |
Quick Links for Secunderabad Healthcare:
-
News
Announcements Brokerage Reports Business Earnings Sector -
Corporate Action
AGM Board Meetings Bonus Dividends EGM Rights Split -
INFORMATION
Bulk Deals Company History MF Holding Listing Info Locations Shareholding -
Financials
Financial Overview Balance Sheet Profit & Loss Cash Flow Ratios Quarterly Results Half Yearly Results Nine Monthly Results Yearly Results -
Annual Report
Auditors Report Chairman's Speech Company Management Directors' Report Finished Goods Raw Materials -
Peer Comparison
Competition Market Cap Price Price Performance Net Sales Net Profit Total Assets Historical Prices
